Log in

Relevant bibliographies by topics / Pharmaceutical Science. Prostate Cancer Cancer

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Pharmaceutical Science. Prostate Cancer Cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical Science. Prostate Cancer Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical Science. Prostate Cancer Cancer"

1

Albarqi, Hassan A., Ananiya A. Demessie, Fahad Y. Sabei, et al. "Systemically Delivered Magnetic Hyperthermia for Prostate Cancer Treatment." Pharmaceutics 12, no. 11 (2020): 1020. http://dx.doi.org/10.3390/pharmaceutics12111020.

Full text

Abstract:

Herein, we report a novel therapy for prostate cancer based on systemically delivered magnetic hyperthermia. Conventional magnetic hyperthermia is a form of thermal therapy where magnetic nanoparticles delivered to cancer sites via intratumoral administration produce heat in the presence of an alternating magnetic field (AMF). To employ this therapy for prostate cancer tumors that are challenging to inject intratumorally, we designed novel nanoclusters with enhanced heating efficiency that reach prostate cancer tumors after systemic administration and generate desirable intratumoral temperatur

APA, Harvard, Vancouver, ISO, and other styles

2

Inoue, Takamitsu, Chikara Ohyama, and Tomonori Habuchi. "Hormonal therapy in prostate cancer." Drug Delivery System 24, no. 4 (2009): 415–20. http://dx.doi.org/10.2745/dds.24.415.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Yang, Changwon, Minkyeong Lee, Gwonhwa Song, and Whasun Lim. "tRNALys-Derived Fragment Alleviates Cisplatin-Induced Apoptosis in Prostate Cancer Cells." Pharmaceutics 13, no. 1 (2021): 55. http://dx.doi.org/10.3390/pharmaceutics13010055.

Full text

Abstract:

Cisplatin is a standard treatment for prostate cancer, which is the third leading cause of cancer-related deaths among men globally. However, patients who have undergone cisplatin can rxperience relapse. tRNA-derived fragments (tRFs) are small non-coding RNAs generated via tRNA cleavage; their physiological activities are linked to the development of human diseases. Specific tRFs, including tRF-315 derived from tRNALys, are highly expressed in prostate cancer patients. However, whether tRF-315 regulates prostate cancer cell proliferation or apoptosis is unclear. Herein, we confirmed that tRF-3

APA, Harvard, Vancouver, ISO, and other styles

4

Sun, Wanxiao, Yaxin Deng, Meihui Zhao, et al. "Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies." Journal of Controlled Release 333 (May 2021): 41–64. http://dx.doi.org/10.1016/j.jconrel.2021.01.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kim, Jae-Heon, Hee-Jo Yang, Chang-Ho Lee, et al. "The Positive Correlations between the Expression of Histopathological Ubiquitin-Conjugating Enzyme 2O Staining and Prostate Cancer Advancement." Pharmaceuticals 14, no. 8 (2021): 778. http://dx.doi.org/10.3390/ph14080778.

Full text

Abstract:

Background: The mTOR signaling pathway is inactivated by AMPK’s tumor-suppressing function. It is recognized that ubiquitin conjugating enzyme 2O (UBE2O), which directly targets AMPK for ubiquitination and degradation, is intensified in human cancers. Methods: This study investigated the clinical data about prostate cancer. Examination was also carried out into tissue microarrays (TMA) of human prostate cancer (n = 382) and adjacent non-neoplastic tissues around prostate cancer (n = 61). The TMA slides were incubated with antibodies against UBE2O, and the cores were scored by the pathologist b

APA, Harvard, Vancouver, ISO, and other styles

6

Lu, Yi. "Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer." Advanced Drug Delivery Reviews 61, no. 7-8 (2009): 572–88. http://dx.doi.org/10.1016/j.addr.2009.03.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chen, Yun, Ya-Hui Tsai, and Sheng-Hong Tseng. "Regulation of ZMYND8 to Treat Cancer." Molecules 26, no. 4 (2021): 1083. http://dx.doi.org/10.3390/molecules26041083.

Full text

Abstract:

Zinc finger myeloid, nervy, and deformed epidermal autoregulatory factor 1-type containing 8 (Zinc finger MYND-type containing 8, ZMYND8) is a transcription factor, a histone H3-interacting protein, and a putative chromatin reader/effector that plays an essential role in regulating transcription during normal cellular growth. Mutations and altered expression of ZMYND8 are associated with the development and progression of cancer. Increased expression of ZMYND8 is linked to breast, prostate, colorectal, and cervical cancers. It exerts pro-oncogenic effects in breast and prostate cancers, and it

APA, Harvard, Vancouver, ISO, and other styles

8

Panda, Pritish Kumar, Shivani Saraf, Ankita Tiwari, et al. "Novel Strategies for Targeting Prostate Cancer." Current Drug Delivery 16, no. 8 (2019): 712–27. http://dx.doi.org/10.2174/1567201816666190821143805.

Full text

Abstract:

: Prostate cancer (PCa) is a worldwide issue, with a rapid increase in its occurrence and mortality. Over the years, various strategies have been implemented to overcome the hurdles that exist in the treatment of PCa. Consistently, there is a change in opinion about the methodologies in clinical trial that have engrossed towards the treatment of PCa. Currently, there is a need to resolve these newly recognized challenges by developing newer rational targeting systems. The ongoing clinical protocol for the therapy using different targeting systems is undertaken followed by local targeting to ca

APA, Harvard, Vancouver, ISO, and other styles

9

Roudsari, Nazanin Momeni, Naser-Aldin Lashgari, Saeideh Momtaz, et al. "Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention." Pharmaceutics 13, no. 8 (2021): 1195. http://dx.doi.org/10.3390/pharmaceutics13081195.

Full text

Abstract:

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various cancers and solid tumors. Relevant connections between the PI3K/Akt/mTOR pathway, cell survival, and prostate cancer (PC) provide a great therapeutic target for PC prevention or treatment. Recent studies have focused on small-molecule mTOR inhibitors or their usage in coordination with other therapeutics for PC treatment that are currently under

APA, Harvard, Vancouver, ISO, and other styles

10

Shajahan, Sulthan, and Arul Amuthan. "COMPARATIVE IN-VITRO ANTICANCER ACTIVITY OF THANGA PARPAM (SIDDHA GOLD DRUG) IN BREAST, LIVER, PROSTATE AND LUNG CANCER CELL LINES." International Journal of Research in Ayurveda and Pharmacy 12, no. 1 (2021): 64–67. http://dx.doi.org/10.7897/2277-4343.120115.

Full text

Abstract:

Thanga parpam is a gold nanoparticle used in Siddha for many chronic and challenging diseases including cancers. Clinically it shows benefit in some cancer types, but not to all types. This study was aimed to compare the in-vitro anticancer activity of Thanga parpam in various cancer cell lines. The particle size and elements were evaluated using Scanning Electron Microscope coupled with Energy Dispersive X-Ray Spectroscopy. Thanga parpam was added to breast adenocarcinoma cells, Human hepatocellular carcinoma cells, Human prostate cancer cells and Human lung adenocarcinoma epithelial cells fo

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Pharmaceutical Science. Prostate Cancer Cancer"

1

Hitron, Anna Elizabeth. "THE INFLUENCE OF ANTIDIABETIC MEDICATIONS ON THE DEVELOPMENT AND PROGRESSION OF PROSTATE CANCER." UKnowledge, 2011. http://uknowledge.uky.edu/gradschool_theses/649.

Full text

Abstract:

The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and time to tumor progression compared to non-diabetics. This retrospective, nested case control study identified patients with prostate cancer (PCa) from the Kentucky Medicaid Database. Cases were diagnosed with PCa and DM and using at least one of the following antidiabetic medications; sulfonylureas, i

APA, Harvard, Vancouver, ISO, and other styles

2

Singh, Shilpa. "SYNTHESIS AND BIOLOGICAL EVALUATION OF SECOND GENERATION ANIBAMINE ANALOGUES AS NOVEL ANTI-PROSTATE CANCER AGENTS." VCU Scholars Compass, 2012. http://scholarscompass.vcu.edu/etd/359.

Full text

Abstract:

Prostate cancer is the most prevalent non-cutaneous cancer among men. Since the 19th century when Virchow first introduced the concept of inflammation in cancer, chemokines and their receptors have garnered a lot of interest. Chemokine receptor CCR5 has been especially implicated in many disease states and recently found to be over expressed in prostate cancer cell lines. Anibamine, a natural CCR5 antagonist discovered in 2004, has been found to have significant anti-prostate cancer activity at micromolar level. To optimize this compound and also discover a novel pharmacophore, exploration of

APA, Harvard, Vancouver, ISO, and other styles

3

Beziere, Nicolas. "Optimisation du concept d'inhibition de Cyclooxygénase dans le traitement du cancer de la prostate." Phd thesis, Université du Droit et de la Santé - Lille II, 2008. http://tel.archives-ouvertes.fr/tel-00519646.

Full text

Abstract:

L'acide acétylsalicylique, molécule dérivée d'extraits de saule, est utilisé depuis des milliers d'années comme antiinflammatoire et analgésique. La découverte au cours des années 80 de la cyclooxygénase, cible de cet inhibiteur enzymatique, a relancé la recherche de nouveaux anti-inflammatoires non stéroïdiens (AINS). C'est la mise en évidence de l'existence de plusieurs isoformes de la COX et l'attribution des effets pharmacologiques des inhibiteurs de cyclooxygénase à ces différents isoformes qui a permis l'émergence de nouvelles thérapeutiques minimisant les effets secondaires gastriques d

APA, Harvard, Vancouver, ISO, and other styles

4

Ho, Yik Khuan (Abby). "A NOVEL CLASS OF IMMUNOPROTEASOME CATALYTIC SUBUNIT LMP2 INHIBITOR AND ITS THERAPEUTIC POTENTIALS IN CANCER." UKnowledge, 2008. http://uknowledge.uky.edu/gradschool_diss/686.

Full text

Abstract:

The immunoproteasome, known to play an important role in MHC class I antigen processing and presentation, have been linked to neurodegenerative diseases and hematological cancers. However, the pathophysiological functions of the immunoproteasome in these diseases are still not very well established. This can be attributed mainly to the lack of appropriate molecular probes that selectively target the immunoproteasome catalytic subunits. Herein, we report the development of a small molecular inhibitor (AM) that selectively targets the major catalytic subunit, LMP2, of the immunoproteasome. We sh

APA, Harvard, Vancouver, ISO, and other styles

5

Arnatt, Christopher Kent. "DEVELOPMENT OF ANTAGONISTS TARGETING CHEMOKINE RECEPTOR CCR5 AND THE CHEMOKINE RECEPTOR CCR5 – MU OPIOID RECEPTOR HETERODIMER." VCU Scholars Compass, 2013. http://scholarscompass.vcu.edu/etd/517.

Full text

Abstract:

The chemokine receptor CCR5 (CCR5) plays an integral role within the inflammatory network of cells. Importantly, CCR5 is a mediator in several disease states and can be targeted using small molecule antagonists. Within this work, CCR5’s role in prostate cancer and HIV/AIDS has been exploited in order to develop potential therapeutics and probes. First, a series of novel compounds was designed by using pharmacophore-based drug design based upon known CCR5 antagonists and molecular modeling studies of the CCR5 receptor’s three-dimensional conformation. Once synthesized, these compounds were t

APA, Harvard, Vancouver, ISO, and other styles

6

Wang, Fulton. "Modeling recovery curves for prostate cancer." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/82362.

Full text

Abstract:

Thesis (S.M.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science, 2013.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (p. 43).<br>In this thesis, I analyze a dataset containing a time series of various bodily functionality scores for patients following 3 different forms of prostate cancer treatment. I propose a parametric model for those function level time series and show promise that the method can be applied to both simulated and real data.<br>by Fulton Wang.<br>S.M.

APA, Harvard, Vancouver, ISO, and other styles

7

Faragalla, Jane Eliza. "Development of isoflavonoid-derived anti-prostatic cancer agents." Access electronically, 2005. http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20060516.121728/index.html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nortcliffe, Andrew. "Nitric oxide donors for the treatment of prostate cancer." Thesis, University of St Andrews, 2013. http://hdl.handle.net/10023/4124.

Full text

Abstract:

Chapter One provides a general introduction into the biology and chemistry of nitric oxide, with particular focus on the role of nitric oxide in cardiovascular disease, cancer and hypoxia. It also details the types of organic functional groups used as nitric oxide donors, with detailed discussion of nitrate esters, furoxans and sydnonimines. Chapter Two discusses prostate cancer. It provides an overview into the development of prostate cancer, prostate cancer staging, and treatment. The key molecular aspects of prostate cancer are detailed, and the types of treatment available outlined. Chapte

APA, Harvard, Vancouver, ISO, and other styles

9

Byrne, Ashleigh Maria. "Functional characterisation of phosphodiesterase 4D7 in prostate cancer." Thesis, University of Glasgow, 2014. http://theses.gla.ac.uk/5275/.

Full text

Abstract:

3’,5’-cyclic adenosine monophosphate (cAMP) is the best studied intracellular second messenger. Adenylyl cyclase (AC) catalyses the synthesis of cAMP from ATP following the stimulation of a G protein coupled receptor (GPCR), and its degradation is catalysed by cAMP phosphodiesterases (PDEs) to allow cessation of signal. cAMP can act to bring about a multitude of varying and often opposing cellular responses, which depend on the stimulus received by the GPCR, the cell type, the cell cycle stage, and the complement of downstream effector molecules within that cell. The cAMP PDE subfamilies expre

APA, Harvard, Vancouver, ISO, and other styles

10

Tamboli, Vibha. "Detection of prostate cancer biomarker using molecularly imprinted polymers." Thesis, Cardiff University, 2017. http://orca.cf.ac.uk/103518/.

Full text

Abstract:

Successful treatment of prostate cancer (PCa) depends on early diagnosis and screening, which currently relies on the measurement of serum prostate specific antigen (PSA) levels. The overarching aim of the project was to generate molecularly imprinted polymers for PCa biomarkers, with subsequent integration with a sensing platform to allow for rapid, point of care detection and monitoring. The initial work involved the use of simple PSA epitopes for epitope imprinting using conventional imprinting techniques. A four amino acid sequence from the Cterminus of PSA was imprinted with MAA, Aam and

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical Science. Prostate Cancer Cancer"

1

name, No. Prostate cancer: Science and clinical practice. Academic Press, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Recent advances in prostate cancer: Basic science discoveries and clinical advances. World Scientific Publishing, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mullins, Patrick James. Prostate cancers: Prevention & control : index of new information for medicine, science, and research with update of progress. ABBE Publishers Association, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Williams, Charles R. That Black men might live: My fight against prostate cancer. Hilton Pub. Co., 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ames, Dave. Me, my cells, and I: A survivor's seriously funny guide to the science of cancer. Sentient Publications, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Madabhushi, Anant. Prostate Cancer Imaging. Image Analysis and Image-Guided Interventions: International Workshop, Held in Conjunction with MICCAI 2011, Toronto, Canada, September 22, 2011. Proceedings. Springer-Verlag GmbH Berlin Heidelberg, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Madabhushi, Anant. Prostate cancer imaging: Computer-aided diagnosis, prognosis, and intervention : international workshop held in conjunction with MICCAI 2010, Beijing, China, September 24, 2010 : proceedings. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mydlo, Jack H., and Ciril J. Godec. Prostate Cancer: Science and Clinical Practice. Elsevier Science & Technology Books, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

(Editor), Jack Mydlo, and Ciril J. Godec (Editor), eds. Prostate Cancer: Science and Clinical Practice. Academic Press, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

H, Mydlo Jack, and Godec Ciril J, eds. Prostate cancer: Science and clinical practice. Academic Press, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaceutical Science. Prostate Cancer Cancer"

1

Kumar, Vivekanandan. "Other Pharmaceutical Agents in the Chemoprevention of Prostate Cancer." In Prostate Cancer: A Comprehensive Perspective. Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2864-9_33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Asad Khan, Md, Salman Ahmad, Irfan Ahmad, and M. Moshahid A. Rizvi. "Anti-Proliferative Activity of Curcumin Loaded PLGA Nanoparticles for Prostate Cancer." In Nanotechnology Applied To Pharmaceutical Technology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70299-5_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Waxman, J. "Carcinoma of the Prostate: Science and Treatment." In Progress in Diagnostics and Therapy of Prostatic Cancer. Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79947-1_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kim, Jung-Ja, Young-Ho Kim, and Yonggwan Won. "Proteomic Pattern Classification Using Bio-markers for Prostate Cancer Diagnosis." In Computational and Information Science. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-540-30497-5_99.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cao, Xiaohuan, Yaozong Gao, Jianhua Yang, Guorong Wu, and Dinggang Shen. "Learning-Based Multimodal Image Registration for Prostate Cancer Radiation Therapy." In Lecture Notes in Computer Science. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46726-9_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lacave, Carmen, and Francisco J. Díez. "Knowledge Acquisition in PROSTANET – A Bayesian Network for Diagnosing Prostate Cancer." In Lecture Notes in Computer Science. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-540-45226-3_182.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, Liping, and Reyer Zwiggelaar. "3D Texton Based Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging." In Communications in Computer and Information Science. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-60964-5_27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stern, Mariana C. "Prostate Cancer in US Latinos: What Have We Learned and Where Should We Focus Our Attention." In Advancing the Science of Cancer in Latinos. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29286-7_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Aljundi, Rahaf, Jérôme Lehaire, Fabrice Prost-Boucle, Olivier Rouvière, and Carole Lartizien. "Transfer Learning for Prostate Cancer Mapping Based on Multicentric MR Imaging Databases." In Lecture Notes in Computer Science. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-27929-9_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fei, Baowei, Viraj Master, Peter Nieh, et al. "A PET/CT Directed, 3D Ultrasound-Guided Biopsy System for Prostate Cancer." In Lecture Notes in Computer Science. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-23944-1_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical Science. Prostate Cancer Cancer"

1

Hardy, Fred. "Abstract A031: Karmanos Cancer Institute Prostate Cancer Advocacy Program." In Abstracts: Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 20-23, 2019; San Francisco, CA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp19-a031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wu, Chun-Hui, Kwoting Fang, and Ta-Cheng Chen. "Applying Data Mining for Prostate Cancer." In 2009 International Conference on New Trends in Information and Service Science (NISS). IEEE, 2009. http://dx.doi.org/10.1109/niss.2009.195.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ricks-Santi, Luisel J., Tshela Mason, Muneer Abbas, et al. "Abstract A69: Identification of prostate cancer genes in the African American Hereditary Prostate Cancer (AAHPC) study." In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 18-Sep 21, 2011; Washington, DC. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1055-9965.disp-11-a69.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

McNicholas, Thomas A., and Neil O'Donoghue. "Endoscopic YAG laser coagulation for early prostate cancer." In Optics, Electro-Optics, and Laser Applications in Science and Engineering, edited by Graham M. Watson, Rudolf W. Steiner, and Joseph J. Pietrafitta. SPIE, 1991. http://dx.doi.org/10.1117/12.43908.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Garcia, MDP, MV Villacañas, E. Laso, A. Corral, MJ Otero, and A. Sanchez. "DI-077 A pharmaceutical care programme to improve pain management in patients with advanced prostate cancer." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.324.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

McMahon, Daria M., Susan E. Steck, L. Joseph Su, et al. "Abstract B05: Multivitamin supplement use and prostate cancer aggressiveness by race in the North Carolina-Louisiana Prostate Cancer Project (PCaP)." In Abstracts: Sixth AACR Conference: The Science of Cancer Health Disparities; December 6–9, 2013; Atlanta, GA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7755.disp13-b05.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Antwi, Samuel, Susan E. Steck, L. Joseph Su, et al. "Abstract B08: Occupational and recreational physical activity in relation to prostate cancer aggressiveness: The North Carolina-Louisiana Prostate Cancer Project (PCaP)." In Abstracts: Sixth AACR Conference: The Science of Cancer Health Disparities; December 6–9, 2013; Atlanta, GA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7755.disp13-b08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Grancharova, Tsenka, Stanislava Simeonova, Bissera Pilicheva, and Plamen Zagorchev. "Synergistic effect of magnetic nanoparticles and chemotherapeutic drugs in cancer." In III. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2021. http://dx.doi.org/10.14232/syrptbrs.2021.op20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ragin, Camille. "Abstract IA03: Prostate Cancer Epidemiology in Black Men." In Abstracts: Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2016; Fort Lauderdale, FL. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7755.disp16-ia03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kohaar, Indu, Sreedatta Banerjee, Lakshmi Ravindranath, et al. "Abstract B42: Development of a urine exosome-based prostate cancer gene expression panel to address racial differences in prostate cancer." In Abstracts: Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2017; Atlanta, GA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7755.disp17-b42.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!